Antibodies against human IL33R and uses thereof

An anti-human IL33R antibody having a human IgG1 or IgG4 isotype but modified in the hinge region at one or more amino acid position between 216-240, and/or in the second inter-domain region at one or more amino acid position between 327-331 between CH2 and CH3, wherein said antibody is selected from:

• a) An anti-human IL33R antibody comprising a heavy chain variable domain comprising a CDR3 region of SEQ ID NO:24, a CDR2 region of SEQ ID NO:23 and a CDR1 region of SEQ ID NO:22 and a light chain variable domain comprising a CDR3 region of SEQ ID NO:33, a CDR2 region of SEQ ID NO:32 and a CDR1 region of SEQ ID NO:31;
• b) An anti-human IL33R antibody, wherein the heavy chain variable domain comprises SEQ ID NO:21 and the light chain variable domain comprises SEQ ID NO:30;
• or
• c) An anti-human IL33R antibody according to a) or b), which is a chimeric antibody, a humanized antibody or a T cell epitope-depleted antibody.

A pharmaceutical composition comprising an anti-human IL33R antibody, wherein said antibody is selected from:

• a) An anti-human IL33R antibody comprising a heavy chain variable domain comprising a CDR3 region of SEQ ID NO:24, a CDR2 region of SEQ ID NO:23 and a CDR1 region of SEQ ID NO:22 and a light chain variable domain comprising a CDR3 region of SEQ ID NO:33, a CDR2 region of SEQ ID NO:32 and a CDR1 region of SEQ ID NO:31;
• b) An anti-human IL33R antibody, wherein the heavy chain variable domain comprises SEQ ID NO:21 and the light chain variable domain comprises SEQ ID NO:30;
• or
• c) An anti-human IL33R antibody according to a) or b) having a human IgG1 or IgG4 isotype but modified in the hinge region at one or more amino acid position between 216-240, and/or in the second inter-domain region at one or more amino acid position between 327-331 between CH2 and CH3;
• d) An anti-human IL33R antibody according to c), wherein said hinge region is modified by replacing the amino acid at position 234 and the amino acid at position 235 with alanine;
• or
• e) An anti-human IL33R antibody according to c), wherein said hinge region is modified by replacing the amino acid at position 235 and the amino acid at position 228 with glutamic acid and proline, respectively;
• and a pharmaceutically acceptable carrier.

An expression vector comprising a nucleic acid encoding an anti-human IL33R antibody or antigen binding fragment thereof selected from:

• a) An anti-human IL33R antibody comprising a heavy chain variable domain comprising a CDR3 region of SEQ ID NO:24, a CDR2 region of SEQ ID NO:23 and a CDR1 region of SEQ ID NO:22 and a light chain variable domain comprising a CDR3 region of SEQ ID NO:33, a CDR2 region of SEQ ID NO:32 and a CDR1 region of SEQ ID NO:31;
• b) An anti-human IL33R antibody, wherein the heavy chain variable domain comprises SEQ ID NO:21 and the light chain variable domain comprises SEQ ID NO:30;
• c) An anti-human IL33R antibody according to a) or b) having a human IgG1 or IgG4 isotype but modified in the hinge region at one or more amino acid position between 216-240, and/or in the second inter-domain region at one or more amino acid position between 327-331 between CH2 and CH3;
• d) An anti-human IL33R antibody according to c), wherein said hinge region is modified by replacing the amino acid at position 234 and the amino acid at position 235 with alanine;
• or
• e) An anti-human IL33R antibody according to c), wherein said hinge region is modified by replacing the amino acid at position 235 and the amino acid at position 228 with glutamic acid and proline, respectively.